Litcius/Paper detail

Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study

Michael E Wechsler, Linda B Ford, Jorge F Maspero, Ian D Pavord, Alberto Papi, Arnaud Bourdin, Henrik Watz, Mario Castro, Natalia M Nenasheva, Yuji Tohda, David Langton, Guido Cardona, Christian Domingo, Hae Sim Park, Kenneth R Chapman, Xuezhou Mao, Yi Zhang, Asif H Khan, Yamo Deniz, Paul J Rowe, Upender Kapoor, Faisal A Khokhar, Leda P Mannent, Marcella Ruddy, Elizabeth Laws, Nikhil Amin, Megan Hardin

2021The Lancet Respiratory Medicine220 citationsDOIOpen Access PDF

Topics & Concepts

MedicineDupilumabAsthmaInternal medicineMEDLINEDermatologyImmunologyExtension (predicate logic)BenralizumabMonoclonalIntensive care medicineAdrenergic beta-AgonistsAdverse effectRespiratory HypersensitivityAsthma and respiratory diseasesPharmaceutical studies and practicesDermatology and Skin Diseases
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study | Litcius